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Distinct contribution of Fc receptors and angiotensin II-depen-
dent pathways in anti-GBM glomerulonephritis.
Background. The contribution of antibody and/or immune-
complex to the pathogenesis of immunologically-mediated glo-
merulonephritis is not fully understood, although it has been
recently clarified that Fc receptors (FcRs) play critical roles in the
inflammatory cascade. We therefore re-evaluated the classical
model of glomerulonephritis, anti-glomerular basement mem-
brane antibody-induced glomerulonephritis (Anti-GBM GN),
from the standpoint of FcRs and also investigated the residual
FcR-independent mechanisms.
Methods. We adopted an Anti-GBM GN mouse model that has
two strains deficient in the FcR g chain [g(2/2)] or FcgRIIB
[RII(2/2)], and analyzed functional (urinary protein, serum
creatinine, BUN) and pathological changes of the glomeruli. For
the analyses of FcR-independent mechanisms, several doses of
nephrotoxic serum were applied, and then mice were treated
either with cobra venom factor or an angiotensin II type 1
receptor antagonist in g(2/2) mice.
Results. In g(2/2) mice, renal injuries were dramatically atten-
uated with an absence of polymorphonuclear cell (PMN) influx,
while RII(2/2) mice suffered accelerated glomerular injuries in
spite of a normal PMN influx. In the absence of FcR-dependent
effects in g(2/2) mice, the FcR-independent pathway lead to
chronic renal damage characterized by mesangial proliferation
and progressive expansion of mesangial area, with monocyte/
macrophage accumulation and with the expression of a smooth
muscle actin in the mesangial cells and interstitium. Those injuries
in g(2/2) mice were not attenuated by the decomplementation,
but completely abolished by using an angiotensin II type 1
receptor antagonist.
Conclusions. Our results clearly demonstrate that FcRs play a
pivotal role in Anti-GBM GN, especially in its acute phase. We
further clarified the existence of FcR and complement-indepen-
dent but antibody-dependent pathway. Furthermore, we found
that those pathological changes were strongly related to the
renin-angiotensin system.
Deposition of antibodies in the renal tissue, either by
reactions directed to the specific antigenic sites or by
random accumulation of immune complex, is considered
one of the essential events that trigger the inflammatory
cascade leading to immunologically-mediated glomerulo-
nephritis (GN) [1]. However, how antibodies activate in-
flammatory cells and how much antibodies contribute to
the glomerular damage is difficult to dissect, because
multifarious mediator systems underlie the cascade in vivo.
Effects of these several systems have been studied most
often in models of GN induced by anti-GBM antibodies,
and was first reported by Lindeman in 1900 and established
by Masugi and co-workers during the 1930s [1]. Anti-GBM
GN consists of two distinct phases, namely a heterologous
phase, resulting from a rapid binding of the injected
heterologous anti-GBM antibodies, and an autologous
phase that is induced when the recipient’s cells react with
its own antibodies against the heterologous immunoglobu-
lin (Ig) previously fixed at the GBM. The role of antibodies
in this model is characterized by classical pathway in which
antibody deposits are followed by activation of comple-
ments and/or accumulation of inflammatory cells, particu-
larly in the acute phase [1, 2].
However, the inflammatory cascade has been redefined
dramatically by extensive studies on Fc receptors (FcRs),
which play critical roles in the inflammation [3]. In the
current study we re-evaluated the contribution of antibod-
ies to the pathogenesis of GN from the standpoint of FcRs
in Anti-GBM GN. Two strains were examined: one has a
genetic depletion of the FcR g chain, known as an essential
molecule for signal transduction and surface expression of
FcRs [3–5]; the other strain is deficient in FcgRIIB, which
inhibits activation signals generated by receptors containing
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immune receptor tyrosine activation motif (ITAM) [6],
FceRI, FcgRIII and FcgRI. Moreover, using g chain
knocked-out mice in the absence of antibody effects via
FcRs, we assessed the residual contribution of the antibod-
ies to pathogenesis and the induction mechanisms that are
FcR-independent but antibody-dependent in GN.
METHODS
Mice
FcR g chain-[g(2/2)] and FcgRIIB-[RII(2/2)] defi-
cient mice were generated by a homologous recombination
method, as previously described in detail [7, 8]. All exper-
iments used 8- to 10-week-old animals, weighing 18 to 23 g,
which were matched with age and sex. Wild-type litter-
mates of each strain [g(1/1), RII(1/1)] were analyzed
distinctively in Anti-GBM GN. Since no significant differ-
ences were found in the kinetics of proteinuria, histology of
glomeruli and PMN accumulation in glomeruli between
wild-type littermates of each strain, the results of g(1/1)
littermates are shown as representative control wild-type
littermates (WT) in Figures 1, 2, 3, 7, and Tables 1 and 2.
Evaluation of proteinuria
Urine samples (10 ml) at each time point were evaluated
for proteinuria as previously described [9]. Briefly, samples
were spotted onto strips of chromatography paper and fixed
in 70% ethanol. The strips were then immersed in staining
solution containing bromophenol blue. Excess dye was
washed in 2% acetic acid and the strips were transferred
into 2% sodium acetate, 10% acetic acid solution to
develop the blue color. A series of bovine serum albumin
(BSA) standards (5000, 3000, 1000, 333, 111, 74, 37 mg%)
were processed with each batch of urine samples. Density
of each spot was determined using Masterscan (Scanalytic,
MA, USA) according to the manufacturer’s instructions.
Finally, the degree of proteinuria in each mouse was
assessed by comparing the density of urine spots with that
of the spots for BSA standards.
Histological analyses
Kidney sections were fixed in 10% formaldehyde and
stained with periodic acid-Schiff’s (PAS) reagent to assess
histological changes by light microscopy. Glomerular poly-
morphonuclear cells (PMNs) were counted in 3-mm-thick
sections that had been stained with PAS. The number of
PMNs were determined in at least 80 glomeruli per mouse
(3 to 4 mice per each time point). Infiltrating monocyte/
macrophage (Mo/Mf) in glomeruli (at least 80 glomeruli)
were determined by staining with rat anti-mouse Mo/Mf
antibody (F4/80; Serotec).
In this study, a monoclonal antibody specific for
a-smooth muscle actin (a-SMA; American Research Prod-
ucts, MA, USA) was applied and subsequently processed
using a streptavidin-biotin immuno-peroxidase method
[10]. These sections were counterstained with hematoxylin.
Approximately 100 glomeruli for each kidney of g(2/2)
mice were graded according to the degree of a-SMA
expression. Glomerular expression of a-SMA was graded
semiquantitatively following the procedure described by
Alpers et al [11]: 0 5 none; 1 5 trace mesangial staining;
2 5 weak, segmental mesangial staining (usually involving
a small minority of glomeruli present); 3 5 strong, segmen-
tal mesangial staining (usually involving a majority of
glomeruli present); 4 5 strong, diffuse mesangial staining
(usually involving all glomeruli present).
Serological analyses
Serum samples at each time point were evaluated for the
concentration of urea nitrogen and creatinine by the most
commonly used procedures, the Urease-Indophenol
method and Jaffe´ method, respectively. The Wako Urea N
B kit and The Wako Creatinine-Test kit (Wako Pure
Chemical Industries, Ltd. Osaka, Japan) were used for
these quantitative determination.
Preparation of nephrotoxic serum and experimental
protocol for Anti-GBM GN induction
Nephrotoxic serum was kindly provided from Kyowa
Hakko Kogyo Co., Ltd. (Mishima, Japan). Mouse GBM
was purified from isolated glomeruli and anti-GBM anti-
bodies were raised in rabbits by repeated immunization
with the purified GBM in complete and incomplete
Freund’s adjuvant. Nephrotoxic serum was decomple-
mented by heating at 56°C for 30 minutes and absorbed
with packed mouse red blood cells [12]. Anti-GBM GN was
induced by intravenous injection of nephrotoxic serum
through orbital plexus vein in mice that had been preim-
munized with rabbit IgG and complete Freund’s adjuvant
four days prior to administration of nephrotoxic serum.
Fig. 1. Proteinuria after the injection of nephrotoxic serum in g(2/2)
mice (F), RII(2/2) (f) mice and control wild-type (E) littermates. Each
point represents the mean 6 SE of more than seven animals. RII(2/2)
mice and control wild-type littermates (WT) were sacrificed at day 7,
because they fell into lethal states. (*P , 0.01 vs. WT, ‡P , 0.01 vs.
RII(2/2) mice, §P , 0.01 versus WT.)
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Nephrotoxic serum at several doses were injected intrave-
nously to each mouse. In control mice, nephrotoxic serum
at a dose of 0.05 ml/20 g body wt was sufficient to induce
proteinuria and severe renal damage. No mice developed
anaphylactic symptoms after the injection of nephrotoxic
serum.
For the excess injection of nephrotoxic serum, nephro-
toxic serum four times more (0.2 ml/20 g body wt) than the
usual dose was injected intravenously to g(2/2) mice.
Five g(2/2) mice were treated with cobra venom anti-
complementary protein (CVF; Sigma Chemical Company,
Poole, Dorset, UK) following a protocol similar to what has
been previously described [13–15]. Each mouse was intra-
peritoneally injected with 5 mg CVF four times, at 12 hour
intervals, before the intravenous injection with nephrotoxic
serum. After the injection of nephrotoxic serum, the intra-
peritoneal treatment with 5 mg CVF was further continued
every two days for 12 days.
Fig. 2. Severity of glomerular damage in g(2/2), RII(2/2) mice and control wild-type littermates (WT). Glomerular damage including endothelial
swelling and vascular thrombosis in RII(2/2) (a, b and c) mice was basically as same as those of WT (d, e and f). However, these changes in RII(2/2)
mice appeared earlier on day 1, and were followed by rapid progression of renal damage accompanied with cellular necrosis including mesangiolysis.
In contrast, renal injuries of g(2/2) mice before day 7 were markedly attenuated (g, h and i). Original magnification, a - i 3250.
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Preparation of angiotensin II type 1 receptor antagonist
and experimental design for the examination of its
effects on Anti-GBM GN
Angiotensin II (Ang II) type 1 receptor antagonist,
TCV-116 (candesartan cilexetil), was synthesized by
Takeda Chemical Industries, Ltd. (Osaka, Japan) [16].
Since TCV-116 is insoluble in water, it was suspended in
5% gum arabic and orally administered (10 mg/kg body
wt/day) to g(2/2) mice and wild-type littermates as previ-
ously described [17]. Administration of vehicle (5% gum
arabic) alone did not affect the results in mice of both
strains.
Mice of each strain were divided into two groups in
which TCV-116 was given 12 hours before (group I) or
three days after (group II) nephrotoxic serum injection. To
all mice of both groups, the reagents were orally adminis-
tered every day. Wild-type mice were killed at day 7 after
nephrotoxic serum injection for histological examination
(N 5 5 in each group), while g(2/2) mice were killed at
day 7, 14, 21 (N 5 3, 3, 5 respectively in each group).
Statistical analyses
Statistical significance was assessed by one-way analysis
of variance followed by Bornferroni/Dunn test. All statisti-
cal analyses were performed using the Stat View 4.5
(Abacus Concepts, Inc., Stanford, CA, USA) analysis pro-
gram.
Each point represents the mean 6 SE in Figures 1, 3, 6,
and 7, and Tables 1 and 2.
RESULTS
In this study, we adopted the augmented Anti-GBM GN
model in which each mouse was preimmunized with rabbit
IgG. Thus, we defined the phase before day 7 as acute
phase. Linear binding of the rabbit anti-mouse GBM Ig and
deposits of C3 along the capillary walls were similarly
observed in mice of each strain, as assessed by immunofluo-
rescense at three hours after the injection of nephrotoxic
serum. Autologous IgG antibodies, which were reactive
with the heterologous Ig (rabbit IgG) previously fixed at the
GBM, were observed from day 3 with the same intensity in
glomeruli of each mouse.
Glomerular damage in RII(2/2) and g(2/2) mice at
the acute phase of Anti-GBM GN
In RII(2/2) mice, proteinuria increased steeply even
from day 1 and developed during the subsequent days (Fig.
1). The amount of urinary protein excretion in wild-type
littermates increased gradually and then reached a closely
comparable level of RII(2/2) mice on day 7. After day 3,
hematuria was also observed in mice of both groups. No
significant difference between control wild-type, g(1/1)
and RII(1/1) mice, was found in kinetics of hematuria and
proteinuria [g(1/1) mice versus RII(1/1) mice (mg/dl):
before nephrotoxic serum i.v., 40.4 6 2.3 vs. 58.6 6 8.1; day
1, 216.2 6 18.6 vs. 193.4 6 15.5; day 3, 1353.1 6 180.5 vs.
1392.9 6 174.6; day 7, 3661.3 6 443.2 vs. 3380.8 6 358.7].
Finally, all mice of both groups fell into lethal state with
massive ascites, while the expected proteinuria in g(2/2)
mice was almost completely abolished. Figure 2 shows the
typical glomerular histology of each mouse at days 1, 3 and
7. The morphological changes of glomeruli in RII(2/2)
mice were basically comparable to those in wild-type
animals, but endothelial swelling and vascular thrombosis
involving platelet accumulation and fibrin deposition ap-
peared at day 1 in RII(2/2) mice, earlier than in the
wild-type, and rapidly progressed with cellular necrosis
including mesangiolysis. Fluffy irregularity and occasional
Fig. 3. Serological changes after the injection of nephrotoxic serum in
g(2/2), RII(2/2) and control wild-type littermates (WT). (A) Blood urea
nitrogen (BUN) levels; (B) serum creatinine levels. Symbols are: in A, (M)
WT; (f) g(2/2); (o) RII(2/2); in B, (V) WT; (v) g(2/2); (f) RII
(2/2). Each point in both panels represents the mean 6 SE of more than
five animals. These functional data of BUN and serum creatinine levels
well reflect the severity of proteinuria and histological changes of the
glomeruli in each mouse. (*P , 0.01 vs. WT, ‡P , 0.01 vs. g(2/2) mice)
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splitting of the GBM in mice of the both groups were
observed. In g(2/2) mice, no platelet aggregation, fibrin
deposition or cellular necrosis in glomeruli could be found.
The levels of serum creatinine and BUN well reflected the
severity of proteinuria and the above-mentioned histologi-
cal changes of the glomeruli (Fig. 3).
Infiltrating PMNs in glomeruli of RII(2/2) and wild-
type mice appeared maximal in number at three hours after
the injection of the nephrotoxic serum (Table 1) and almost
same in the both groups. Surprisingly, in g(2/2) mice
nephrotoxic serum injection did not induce such a PMN
accumulation in glomeruli.
Glomerular damage caused by FcR-independent pathway
of Anti-GBM GN in g(2/2) mice
Kinetics of proteinuria in g(2/2) mice was obviously
different from that in other two groups (Fig. 1). In g(2/2)
mice, small increment of proteinuria was found from day 3
and moderate proteinuria continued after day 7. Distinct
morphological changes in glomeruli, which were character-
ized by mesangial proliferation and glomerular enlarge-
ment with Mo/Mf infiltration, were revealed after day 7
(Fig. 4a; see color plate on p. 1172). Electron microscopic
studies demonstrated the progressive expansion of mesan-
gial areas along the clinical course (Fig. 4b). Occasionally,
crescentic formation could be also detected in the glomer-
uli at days 14 and 21.
To investigate whether these mesangial changes were
accompanied with phenotypical changes of the glomerular
mesangial cells (MC), we performed immunostaining of
a-SMA (Fig. 4c). The degree of the a-SMA expression in
MC, peripheries of Bowman’s capsules and interstitium
was correlated with the severity of proteinuria. Significant
increase in the number of the infiltrating Mo/Mf in
glomeruli (Table 2) coincided with the elevation of the
a-SMA expression (Fig. 5).
Inhibitory effects of a selective antagonist for angiotensin
II type 1 receptor on the FcR-independent pathway of
Anti-GBM GN
The aforementioned glomerular changes observed in
later stages of the disease in g(2/2) mice appeared to be
induced in a dose dependent manner by nephrotoxic serum
(Fig. 6), but not to be attenuated by decomplementation
with cobra venom factor [treated g(2/2) mice versus
control g(2/2) mice: before i.v., 56.5 6 7.6 vs. 67.5 6 8.4;
day 1, 44.2 6 10.2 vs. 63.2 6 7.6; day 3, 100.0 6 27.6 vs.
133.9 6 33.9; day 7, 2179.0 6 704.5 vs. 759.5 6 275.4; day
14, 2050.2 6 969.0 vs. 1998.7 6 573.3].
To investigate the pathological mechanisms of the later
phase, we tried manipulation of FcR-independent pathway
by using a selective antagonist for the Ang II type 1
receptor, TCV-116. TCV-116 was orally administered every
day, and started 12 hours before (group I), or three days
after (group II) nephrotoxic serum injection. Control wild-
type mice of groups I and II fell into lethal states with
massive proteinuria and severe renal damage seven days
after nephrotoxic serum injection like untreated wild-type
mice (Fig. 7). Although TCV-116 did not have any effects
on the amount of linear deposition of the injected antibod-
ies and autologous antibodies along the GBM, g(2/2)
mice in group I demonstrated a drastic improvement in
proteinuria and morphological changes of the glomeruli
(Fig. 8a), with the exception of significant Mo/Mf accumu-
lation after day 7 (day 14, 2.01 6 0.25; day 21, 1.44 6 0.48).
In group II g(2/2) mice, while renal injuries developed
transiently from day 7 to 10 like untreated g(2/2) mice
(Fig. 8b), mesangial proliferation, glomerular enlargement
and Mo/Mf accumulation in glomeruli (from 4.8 6 0.61 at
day 10 to 1.66 6 0.58 at day 21) were markedly reduced at
day 21 by further administration of TCV-116 (Fig. 8c).
DISCUSSION
Renal injuries in the acute phase of Anti-GBM GN were
markedly attenuated in g(2/2) mice despite normal in-
flammatory responses to other stimuli such as complements
and/or preimmunized cellular immunity. It is therefore
concluded that functional FcRs are essential molecules in
the acute phase of Anti-GBM GN, as same as in reverse
passive Arthus reaction [18].
Severity of renal damage in the so-called heterologous
phase is known to be dependent on glomerular influx of
PMNs [19]. To assess the relevant Fc receptor-bearing cell
Table 1. Glomerular polymorphonuclear cell (PMN) counts in anti-glomerular basement membrane glomerulonephritis (Anti-GBM GN)
Mouse
Before
NTS i.v.
After NTS
3 hours 6 hours day 1 day 3 day 7
Wild-type 0.62 6 0.33 5.60 6 0.27 2.67 6 0.43 1.81 6 0.21 1.63 6 0.07 1.00 6 0.09
N 3 3 3 3 4 4
g(2/2) 0.58 6 0.29 0.48 6 0.02a,b 0.89 6 0.18a,b 0.77 6 0.10a 0.68 6 0.04a 0.83 6 0.12
N 3 3 3 3 4 4
RII(2/2) 0.51 6 0.17 4.12 6 0.27 3.22 6 0.30 1.30 6 0.10 1.07 6 0.25c 1.01 6 0.05
N 3 3 3 3 3 4
Glomerular polymorphonuclear cell (PMN) counts in g(2/2), RII(2/2) mice and control wild-type littermates (WT). Glomerular PMNs were
counted before nephrotoxic serum (NTS) injection (before NTS i.v.) and at 3 and 6 hours and days 1, 3, 7 after NTS injection. The numbers of PMNs
were expressed as the mean 6 SE per glomerular cross section.
a P , 0.01 vs. wild-type mice
b P , 0.01 vs. RII(2/2) mice
c P , 0.01 vs. wild type mice
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types, we evaluated the number of PMNs in glomeruli.
Since infiltrating PMNs in glomeruli of RII(2/2) mice and
wild-type littermates were almost same in number and
kinetics of their infiltration, we propose that immediate
morphological and functional alterations of glomeruli in
RII(2/2) mice were caused by hypersensitivity to Ig-
triggering (via FcRs) because of FcgRIIB deficiency, which
may result in excessive release of proteolytic enzymes and
proinflammatory mediators from infiltrating PMNs.
On the other hand, the absence of PMNs in the glomer-
uli of g(2/2) mice can be one of the major reasons that
g(2/2) mice were saved from glomerular endothelial
injuries in the acute phase of Anti-GBM GN. Although
depletion of complements is known to result in an attenu-
ation of this phase [19, 20], our data revealed that FcRs,
except for FcgRIIB, play a pivotal role in initiating the
Fig. 5. Correlation between the extent of the glomerular expression of
a-smooth muscle actin (a-SMA) and glomerular monocyte/macrophage
(Mo/Mf) counts in g(2/2) mice. The glomerular expression of a-SMA
was graded by semiquantitative procedure in each glomerulus (Methods
section) and the average was determined as the a-SMA score of each
g(2/2) mouse. The a-SMA score was well correlated with the number of
infiltrating Mo/Mf in glomeruli (y 5 0.73806 1 2.1748x; R2 5 0.948).
Fig. 6. Severity of proteinuria in g(2/2) mice depends on the dose of the
injected nephrotoxic serum. The glomerular changes observed in later
stages of the disease in g(2/2) mice appeared earlier and more severe
when treated four times with nephrotoxic serum (F) rather than only once
(E). Each point represents the mean 6 SE of more than four animals. *P ,
0.05, ‡P , 0.01 vs. 1 3 nephrotoxic serum/g(2/2) mice.
Fig. 7. Effects of the angiotensin II (Ang II) type 1 receptor antagonist on
the severity of proteinuria in anti-GBM glomerulonephritis. Mice of each
strain were divided into two groups in which the selective antagonist for
Ang II type 1 receptor, TCV-116, was given 12 hours before (group I) or
three days after (group II) nephrotoxic serum injection. Each point
represents the mean 6 SE of more than five mice. Symbols are: (F)
g(2/2) group I; (E) g(2/2) group II; (f) wild-type littermate group I;
(M) wild-type littermate group II. *P , 0.01 vs. wild-type littermate group
I, ‡P , 0.01 vs. wild-type littermate group II, §P , 0.03 vs. g(2/2) group
II.
Table 2. Glomerular monocyte/macrophage (Mo/Mø) counts in anti-GBM glomerulonephritis
Before
NTS i.v.
After NTS
day 1 day 3 day 7 day 14 day 21
WT 0.68 6 0.27 1.54 6 0.16 1.56 6 0.25 2.13 6 0.09 ND ND
N 3 3 3 3
g(2/2) 0.61 6 0.22 1.02 6 0.10 1.40 6 0.22 1.74 6 0.25 7.70 6 0.57a 5.64 6 0.65a
N 3 3 3 3 3 3
Glomerular Mo/Mø counts in g(2/2) mice and control wild-type littermates (WT). Glomerular Mo/Mø were counted before nephrotoxic serum
(NTS) injection (before NTS i.v.) and at days 1, 3, 7, 14, and 21 after NTS injection. Since WT fell into lethal state at day 7, the numbers of Mo/Mø
at days 14 and 21 in WT were not determined (ND). Data are expressed as the mean 6 SE per glomerular cross section.
a P , 0.01 versus g(2/2) mice at day 7
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inflammatory cascade leading to the infiltration of PMNs in
glomeruli. It has been clarified that FcRs on local resident
cells are important in inflammation [3, 18, 21] and it may be
thus possible that the phenotypical variations of FcR
expression contribute to the severity of antibody/immune
complex-mediated diseases in individual or organ specific
conditions. The role of FcRs on intrinsic glomerular cells,
particularly mesangial cells [22–24], in triggering the in-
flammation has not been clearly determined yet, and is now
under vigorous investigation.
The kinetics of proteinuria in g(2/2) mice suggested
that the FcR-independent pathway underlay and led
g(2/2) mice to have different morphological changes in
Fig. 4. Histological changes of glomeruli in g(2/2) mice at day 21 after
the injection of nephrotoxic serum. (a) Light microscopy showing mesan-
gial proliferation and glomerular enlargement as a consequence of
FcR-independent mechanisms. (b) Expansion of mesangial areas was
revealed by electron microscopy (*mesangial cell). (c) a-Smooth muscle
actin (a-SMA) expression could be detected in mesangial cells, peripher-
ies of Bowman’s capsules and interstitium after day 7 in addition to renal
arteries and arterioles. Original magnification, a 3250, b 32700, c 3100.
™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™3
Fig. 8. Effects of the angiotensin II (Ang II) type 1 receptor antagonist on
morphological changes of g(2/2) mice in anti-GBM glomerulonephritis.
A selective antagonist for Ang II type 1 receptor, TCV-116, was orally
administered every day, starting 12 hours before (group I), or three days
after nephrotoxic serum injection. (a) Mesangial proliferation and Mo/Mf
accumulation in the glomeruli at day 21 are drastically improved in group
I of g(2/2) mice. (b) In group II of g(2/2) mice, although transient
development of renal injuries like in the untreated g(2/2) mice are
observed from day 7 to day 10, further administration of the Ang II type
1 receptor antagonist markedly reduced these changes (c) (original
magnification; a, b, c 3100).
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glomeruli, which were characterized by mesangial prolifer-
ation, progressive expansion of mesangial area with
Mo/Mf accumulation, and occasional crescentic forma-
tion. Furthermore, these changes developed with a-SMA
expression, a well known marker of the phenotypical
change to cells like myofibroblasts [11]. Therefore, we
hypothesized that these glomerular injuries caused by the
FcR-independent pathway might result in the development
of progressive glomerulosclerosis. Because it has been
recently clarified that the renin-angiotensin system (RAS)
contributes to chronic progression of GN [25–27], we tried
manipulation of FcR-independent pathway (the late
phase), blocking the action of Ang II by an Ang II type 1
receptor antagonist.
Drastic improvement in proteinuria and morphological
changes of the glomeruli without Mo/Mf accumulation was
found in group I of the treated g(2/2) mice. It means that,
in addition to the hemodynamic alteration previously de-
scribed [28, 29], Ang II may play a direct role in the
development of glomerulosclerosis through its ability to
activate the immunological cascade, such as Mo/Mf accu-
mulation in the glomeruli. Sugaya et al confirmed that
chronic glomerular damages in Anti-GBM GN were pre-
vented in Ang II type 1 receptor knocked-out mice [30],
concomitant with disappearance of several cytokine/che-
mokine expressions and no accumulation of inflammatory
cells in glomeruli, in contrast to wild-type littermates
(personal communication, T. Sugaya). Thus, the direct
effects of Ang II on the production of chemotactic factors
and/or the expression of adhesion molecules in the glomer-
uli should be analyzed in future studies.
However, transient development of glomerular injuries
in g(2/2) mice of group II suggested that the RAS was
operating latently even during the early stage. The RAS in
kidney has long been known as a circulating hormone
system, but it has recently also become regarded as a local
endocrine system serving paracrine and autocrine func-
tions. Apart from systemic hemodynamics, intrarenal RAS
may be activated and play an important role as a regulator
of renal function under physiological and/or pathophysio-
logical conditions in the kidney. Several reports demon-
strate that intrarenal RAS modifies mesangial cell function,
including proliferation and extracellular matrix synthesis,
via up-regulation of transforming growth factor-b (TGF-b)
expression [31–33]. Ang II also enhances mesangial uptake
of macromolecules such as aggregated IgG in a FcR-
independent manner [34]. In this aspect, it is interesting
that primary cultured mesangial cells from g(2/2) mice
can produce some inflammatory chemokines under the
treatment with aggregated IgG (our unpublished observa-
tion). Although the precise inducer of intrarenal RAS
remains uncertain, isolated perfusion kidney models sug-
gest that deposition of anti-GBM antibodies at glomeruli
directly cause increments of renal renin activity indepen-
dently of hemodynamic changes or of inflammatory cell
infiltration [35, 36]. These findings indicate that deposition
of anti-GBM antibodies induced renal damage in g(2/2)
mice via local activation of RAS, and probably also accom-
panied with systemic activation of RAS.
In this study, we demonstrate two distinct roles of
antibodies, with regard to FcR-dependent and -indepen-
dent pathways, and also found that the latter pathway is
strongly related to RAS. Since blocking of RAS did not
prevent the progression of renal damage in control wild-
type mice, the FcR-dependent pathway might cause severe
renal damage by itself. It means that both pathways may
cooperatively determine the features of antibody/immune
complex-mediated GN. Furthermore, glomerular injuries
in g(2/2) mice of group II were markedly reduced at day
21 by further administration of TCV-116, indicating that
prevention of the effects of Ang II could reduce and limit
the manifestation of pre-existing glomerular injury in the
absence of FcR-dependent damage. Taken together, it is
suggested that targeting to these control elements, FcR and
RAS, may provide a potent therapeutic approach for GN,
although further investigations into the FcR-independent
pathway are needed, for example, the interaction between
cellular immunity and RAS.
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APPENDIX
Abbreviations used in this article are: a-SMA, a-smooth muscle actin;
Ang II, angiotensin II; BSA, bovine serum albumin; FcR, Fc receptor;
GBM, glomerular basement membrane; GN, glomerulonephritis; Ig,
immunoglobulin; Mo/Mf, monocyte/macrophage; PAS, periodic acid
Schiff’s; PMN, polymorphonuclear cell; RAS, renin-angiotensin system;
TCV-116, angiotensin II type 1 receptor antagonist.
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